A case of severe and prolonged γ‐hydroxybutyrate ( GHB ) withdrawal syndrome successfully managed with a slow benzodiazepine and baclofen taper
Drug and Alcohol Review · 2025
DOI: 10.1111/dar.13911 ↗Kurz gefasst
Fallbericht in der Zeitschrift Drug and Alcohol Review, 2025. Verfasst von Rachit Gupta und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Addiction Medicine, St Vincent's Hospital, Melbourne, Australia. Hauptthemen laut MEDLINE: Substance Withdrawal Syndrome, Baclofen, Sodium Oxybate, Benzodiazepines. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Introduction γ‐hydroxybutyrate (GHB) is a GABA‐B agonist that rapidly produces effects that are likened to both alcohol and MDMA/ecstasy. GHB use can lead to neuroadaptation with a characteristic withdrawal syndrome. There is currently a paucity of data on the progression of GHB withdrawal, however, due to the drug's short half‐life it is generally considered to be typically 5–7 days, although some cases can be severe and complicated by life threatening delirium. Here, we present a case of severe GHB withdrawal, which recurred on multiple occasions over 56 days, despite initial clinical stabilisation on each occasion and toxicological evidence of abstinence from GHB between episodes. Case Presentation A male patient in his 30s presented with agitated delirium on a background of severe GHB use disorder with a 15‐year history of daily high dose GHB use. Following 3 hospital admissions over 8 weeks, all requiring intravenous sedation and tracheal intubation, the patient's withdrawal delirium was successfully treated with a slow benzodiazepine and baclofen wean over a period of 6 months. Relapse to GHB use between hospitalisations was excluded toxicologically via blood analysis performed at an institute of forensic pathology. Discussion and Conclusions This case highlights that GHB withdrawal can be more prolonged than previously reported in the literature and in some cases may require slow and prolonged tapering of treatment to prevent re‐emergence of delirium. Similar to previous case reports, benzodiazepines and GABA‐B receptor agonists appear to be appropriate drug classes to manage GHB withdrawal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Addiction Medicine, St Vincent's Hospital, Melbourne, Australia.
- Department of Medicine, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.
ORCID-Profile: Rachit Gupta
Zitieren
APA
Gupta, R., Moon, G., Bonomo, Y., & Pastor, A. (2025). A case of severe and prolonged γ‐hydroxybutyrate ( GHB ) withdrawal syndrome successfully managed with a slow benzodiazepine and baclofen taper. Drug and Alcohol Review. https://doi.org/10.1111/dar.13911
Vancouver
Gupta R, Moon G, Bonomo Y, Pastor A. A case of severe and prolonged γ‐hydroxybutyrate ( GHB ) withdrawal syndrome successfully managed with a slow benzodiazepine and baclofen taper. Drug and Alcohol Review. 2025. doi:10.1111/dar.13911
BibTeX
@article{Gupta2025,
author = {Gupta, Rachit and Moon, Greta and Bonomo, Yvonne and Pastor, Adam},
title = {A case of severe and prolonged γ‐hydroxybutyrate ( GHB ) withdrawal syndrome successfully managed with a slow benzodiazepine and baclofen taper},
journal = {Drug and Alcohol Review},
year = {2025},
doi = {10.1111/dar.13911}
}
EUVIMED